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Abstract
Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of ischemic stroke in patients with
non-valvular atrial fibrillation (AF) in England and Wales from the UK National Health Service (NHS) perspective
and estimate value to decision making of further research.Methods.We developed a cost-effectiveness model to com-
pare warfarin (international normalized ratio target range 2–3) with directly acting (or non–vitamin K antagonist)
oral anticoagulants (DOACs) apixaban 5 mg, dabigatran 150 mg, edoxaban 60 mg, and rivaroxaban 20 mg, over 30
years post treatment initiation. In addition to death, the 17-state Markov model included the events stroke, bleed,
myocardial infarction, and intracranial hemorrhage. Input parameters were informed by systematic literature reviews
and network meta-analysis. Expected value of perfect information (EVPI) and expected value of partial perfect infor-
mation (EVPPI) were estimated to provide an upper bound on value of further research. Results. At willingness-to-
pay threshold £20,000, all DOACs have positive expected incremental net benefit compared to warfarin, suggesting
they are likely cost-effective. Apixaban has highest expected incremental net benefit (£7533), followed by dabigatran
(£6365), rivaroxaban (£5279), and edoxaban (£5212). There was considerable uncertainty as to the optimal DOAC,
with the probability apixaban has highest net benefit only 60%. Total estimated population EVPI was £17.94 million
(17.85 million, 18.03 million), with relative effect between apixaban versus dabigatran making the largest contribu-
tion with EVPPI of £7.95 million (7.66 million, 8.24 million). Conclusions. At willingness-to-pay threshold £20,000,
all DOACs have higher expected net benefit than warfarin but there is considerable uncertainty between the
DOACs. Apixaban had the highest expected net benefit and greatest probability of having highest net benefit, but
there is considerable uncertainty between DOACs. A head-to-head apixaban versus dabigatran trial may be of value.
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Atrial fibrillation (AF) is the most common cardiac
arrhythmia.1 Prevalence of AF in the United Kingdom,
including undiagnosed cases, has been estimated at 2.4%
and prevalence roughly doubles with each decade of age.2,3
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AF substantially increases the risk of thromboembolic
stroke due to blood pooling in the left atrium and systemic
embolization to the brain. More than 20% of the 130,000
annual strokes in England and Wales are attributed to AF.
Approximately 2 out of 10 stroke patients do not survive
hospital admission, one third recover in 1 month, and the
remainder have disabilities needing rehabilitation, making
stroke the leading cause of adult disability.4
Warfarin is an effective oral anticoagulant for the pre-
vention of stroke in patients with AF.5 Recent estimates
suggest approximately 300,000 AF patients in the United
Kingdom were prescribed warfarin in 2016.6,7 Warfarin-
related bleeding is one of the top five reasons for hospita-
lization for adverse drug effects in England8 because of
the narrow therapeutic index and numerous drug and
dietary interactions. Although the approximate acquisi-
tion cost of warfarin is only £10 per patient per year, the
requirement for therapeutic monitoring means that the
estimated annual cost of managing a patient on warfarin
in the National Health Service (NHS) in England and
Wales is approximately £283, giving a national annual
spend of over £86 million on AF patients.7 A 2014 NICE
(National Institute for Health and Clinical Excellence)
report estimated that 29% of AF patients received no
treatment, that 22.5% of patients were receiving only
aspirin, and that many receiving anticoagulation are not
in the optimal therapeutic range.7
The class of directly acting (or non–vitamin K antago-
nist) oral anticoagulants (DOACs) include dabigatran (a
direct inhibitor of clotting factor II), rivaroxaban, apixa-
ban, edoxaban, otamixaban, and betrixaban (which are
factor X inhibitors). These agents have a more rapid
onset and offset of action than warfarin and are consid-
ered to have more predictable dosing requirements,
increasing convenience, and reducing the need for drug
monitoring.9 The estimated annual acquisition cost per
patient of new anticoagulants is substantially higher than
that of warfarin and will remain so until patent expiry
(e.g., 2020 for rivaroxaban). However, the higher acqui-
sition cost could be offset by the reduced need for thera-
peutic monitoring through anticoagulation services, by
increased effectiveness, or by improved safety.
DOACs have been evaluated in clinical trials as an alter-
native to lifelong warfarin for the prevention of stroke in
patients with AF. Some UK studies have assessed cost-
effectiveness of individual DOACs10,11 and, more recently,
compared multiple DOACs.12–14 However, none of these
include edoxaban and all have based their efficacy estimates
on individual trials rather than a network meta-analysis
(NMA) of all available trials. There is a need to simultane-
ously compare cost-effectiveness of all DOACs and war-
farin in a single model that pools all the available evidence
and to estimate the value of further clinical research.
Defining optimal as the strategy with the greatest
expected net benefit, our objective is to determine the
optimal first-line anticoagulant in the prevention of
ischemic stroke for patients with non-valvular AF and
not contraindicated to warfarin in the NHS and to esti-
mate the value of further clinical research on the effec-
tiveness of DOACs. Patients include those with
paroxysmal, persistent, or permanent AF who are con-
sidered eligible for anticoagulation by their physician.
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The article is organized as follows. The methods section
first describes the model structure, then describes treat-
ment strategies and switching rules, then describes
sources and assumed or estimated values for the model
inputs, and closes by describing sensitivity analyses. We
then give the results of our economic evaluation and fin-
ish with a discussion of our findings in the context of
previous research and implications for policy.
This work was part of a larger project on the effective-
ness and cost-effectiveness of DOACs for AF and for the
primary prevention, treatment, and secondary prevention
of venous thromboembolic disease.15 The clinical results
and headline cost-effectiveness results have been pub-
lished elsewhere,16 but the present article gives greater
detail on the cost-effectiveness analysis. We additionally
present results of a full value of information analysis.
Methods
We performed a search of the literature to identify previ-
ous model-based cost-effectiveness analyses addressing
our decision question (for full details see Sterne et al15
and Lopez-Lopez et al16). We developed the structure of
our models from a critical appraisal of these previous
models together with discussions with clinical experts
and patient representatives. We chose to develop a new
model structure, as no previous model had compared all
relevant DOACs or included all details identified as rele-
vant by our clinical experts; however, our model shared
many features with previous models. Our economic eva-
luation was conducted in parallel to a systematic review
and NMA of efficacy and safety data.15,16
Model Structure
We used a Markov model with a cycle length of 3
months and time horizon 30 years to compare patients
assigned to warfarin or DOAC as first-line treatment.
The model structure is illustrated in Figure 1. Patients
enter the model in the AF well state, where they are
assumed to have no history of stroke, myocardial infarc-
tion (MI), bleeding or intracranial hemorrhage (ICH).
At any state in this model, patients can experience an
ischemic stroke, extracranial bleed, ICH, MI, transient
ischemic attack (TIA), systemic embolism (SE), or all-
cause death. No distinction is made between the severities
of ischemic stroke. An extracranial bleed includes major
or non-major clinically relevant bleed, without distin-
guishing bleed location (e.g., gastrointestinal bleeding).
Non–clinically relevant bleeds are not explicitly modelled
as their impact on costs and utilities is assumed to be low.
All-cause death includes fatal strokes, bleeds, ICH, and
MI as many randomized controlled trials (RCTs) do not
report cause specific mortality. States are used to record a
Figure 1 Illustration of the Markov model for atrial fibrillation. Patients can experience transient events (TIA or SE) but stay in same
health state, with possibly changed treatment, thereafter. B, clinically relevant bleed; ICH, intracranial hemorrhage; MI, myocardial
infarction; S, ischemic stroke. Adapted from Sterne et al. (2017)15 under Creative Commons Attribution (CC BY 4.0) license.
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history of stroke, MI, bleed, or ICH and states represent-
ing a history of one, two, three, or all four of these events
differ in their costs, utilities, and risks of future events. SE
and TIA have a transient cost and disutility but are
assumed not to have permanent effect on event risks. As
patients age in the model event rates, utilities, and costs
change as described below. Apixaban and dabigatran
have different dose recommendations for older and
younger patients but our model compared only the higher
doses (apixaban 5 mg and dabigatran 150 mg) that are
recommended for younger patients, and makes the simpli-
fying assumption that dose does not reduce with age.17 It
should be noted that the price of the different doses are
the same (Table 5 in Appendix 1). Lower doses, with dif-
ferent event rates, are explored in sensitivity analysis.
The patient cohort represented an ‘‘average’’ patient
with age 70 (SD = 8) years and 60% male, with charac-
teristics chosen to match average patients in the RCTs
identified in the efficacy and safety review.15,16 These
RCTs were considered to be representative of the AF
population in England and Wales. Different ages at treat-
ment initiation were explored in sensitivity analyses dis-
cussed below. These model assumptions are summarized
in Table 1.
Treatment Strategies and Treatment Switching
The reference first-line treatment strategy was warfarin
with international normalized ratio (INR) target range
of 2 to 3 with the option to switch to no treatment. The
DOACs comparator strategies were apixaban 5 mg twice
daily, dabigatran 150 mg twice daily, edoxaban 60 mg
once daily, and rivaroxaban 20 mg once daily, doses rec-
ommended by NICE,17 all with the option to switch to
warfarin INR 2 to 3 and then no treatment, or directly to
no treatment following serious adverse events. Aspirin is
not recommended by NICE so is not included as a first-
line strategy for comparison.17 Our model only incorpo-
rated treatment switching as a result of an acute event.
Switching from DOAC to warfarin or no treatment was
modelled as a probability of switching following acute
events, with details below. We were unable to include
betrixaban due to lack of evidence.
The same model structure is used for the different
first-line treatment options. If a patient switches from a
DOAC to warfarin, they maintain their event history but
their remaining lifetime is estimated assuming event
risks, costs, and utilities corresponding to the warfarin
model. Various treatment switching rules and probabil-
ities were assumed. Due to the higher risk of MI on dabi-
gatran, patients on dabigatran who experience an MI are
assumed to always switch to warfarin,18,19 while patients
on other treatments do not switch following an MI.
Patients who experience an ICH, whether on warfarin or
a DOAC, will always switch to no treatment. Following
a stroke or bleed, patients have a treatment switching
probability, specified in Table 2, of switching from a
DOAC to warfarin or from warfarin to no treatment.
Patients experiencing SE and TIA make the same transi-
tion with a lower treatment switching probability. We
used Beta distributions to best represent clinical advice
on the uncertainty in these probabilities.
Model Inputs
A systematic literature review was used to identify RCTs
comparing DOACs to warfarin and reporting on the
events of interest in our model,15,16 This search identified
23 RCTs for inclusion, which were synthesized in a com-
peting risks NMA. The hazard ratios estimated from the
NMA for the seven events relative to warfarin are sum-
marized in Table 7 of the appendix. Note that evidence
on TIA was weak, as represented by very wide credible
intervals that indicate no evidence of a difference between
treatments on this outcome. The absolute hazard of
events on warfarin were estimated using a competing
risks single-treatment meta-analysis based on data from
RCTs that included a warfarin arm.20 Because our model
allows treatment switching to ‘‘no treatment,’’ we require
event hazard estimates under no treatment. We estimated
these hazard ratios of events on warfarin compared to
placebo/no treatment using a meta-analysis of studies
identified in a published systematic review.5,15,16 We
assumed there was no effect of taking warfarin on MI
rates due to a lack of evidence.
A baseline all-cause mortality rate for patients on each
DOAC was estimated using NMA but Office of National
Statistician (ONS) lifetables were used to estimate the
increase in underlying all-cause mortality as the model
cohort ages, assuming a 60/40 male/female gender split.
Non-mortality event rate estimates represent an average
over the characteristics of the RCT populations. The
effect of prior events on future risks are reported in the
appendix (Table 6). A Swedish cohort study of AF
patients21 estimated hazard ratios for stroke, ICH,
bleeds, and MI in patients with a history of each of these
events compared to patients with no history of these
events. A Danish registry study of AF patients22 reported
the effect of history of MI or stroke on mortality. We
assumed the impact of a history of clinically relevant
bleed or ICH on mortality would be the same as that for
stroke, but explored this in sensitivity analysis. The effect
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of prior events on future risks was assumed to be additive
on log hazard scale.
Acute event costs and costs per cycle are summarized in
Table 2; when these were based on NHS reference costs,
uniform distributions were assumed due to the absence of
evidence on uncertainty. The cost for a DOAC was
calculated using the BNF (British National Formulary).23
It was assumed that DOACs incurred no monitoring or
administration costs. Warfarin costs were estimated from a
NICE report and, due to lack of evidence on uncertainty,
assumed to follow a uniform distribution with upper and
lower bounds 50% and 150% of this estimate,
Table 1 Main Assumptions in the Atrial Fibrillation Model
Assumption Brief Justificationa
Does not include minor non–clinically relevant bleeds as
transient events
These would have little effect on total cost and QALYs
No distinction between severity of ischemic strokes No evidence that treatments differ in severity of stroke;
instead averaged over mild, moderate, and severe stroke in
rates, costs, and utilities
SE assumed to be a transient event without long-term
consequences
Published literature and clinical advice
Dose of apixaban and dabigatran given does not reduce as
patients age
Clinical advice but explored lower doses in sensitivity analysis
and found low dose apixaban optimal
Bleeds and ICH (and with it, hemorrhagic stroke) have same
effect on future risk of death as stroke
Clinical advice as no published evidence but sensitivity
analysis assuming no effect on mortality did not change
results
Patients on dabigatran who experience an MI will always
switch to warfarin
Clinical advice but sensitivity analysis assuming they do not
switch did not change results
Patients switch to no treatment after ICH/hemorrhagic stroke Clinical advice
Patients may switch (with an assumed probability) from
DOAC to warfarin or warfarin to no treatment after
ischemic stroke, bleed, SE, or TIA
Clinical advice
Patient samples in RCTs identified by our systematic review
are representative of the AF population in England and
Wales
Relative effectiveness and warfarin event probabilities came
from RCTs; differences from general population are a
limitation
Event rates and relative treatment effects are assumed not to
vary with age
Mortality did increase with age; no evidence on age variation
of treatment effects; evidence on event rates based on RCTs
which averaged over patient types
Relative mortality rate in AF patients relative to the general
population does not vary with age
As our cohort runs from age 70 to end of life, variations will
approximately average out
Warfarin treatment costs over 3 months are taken from the
NICE costing report; uncertainty in this is represented using
a uniformly distribution from 50% to 150% of the NICE
costing report estimate
No uncertainty assessment was provided in source so normal
distribution was inappropriate; threshold analysis found
warfarin price should reduce from £404.52 annually to
2£1393.79 to have highest expected net benefit
Assumes no monitoring or administration costs for DOACs Well established advantage of DOACs over warfarin9,55;
however, sensitivity analysis assuming monitoring cost
(50% that of warfarin) had no impact on results
Assumes post-ICH management costs to be similar to post-
ischemic stroke management costs
Clinical advice
Combined management costs for post-multiple event states
(eg, MI + stroke) to be the maximum of management
costs for constituent events
Clinical advice that costs would not be additive as therapy
and other management strategies may be similar and not
duplicated
Assumed quality of life for patients with a history of multiple
events to be multiplicative combination of quality of life for
constituent events
Assumption to capture impact of further events
AF, atrial fibrillation; DOAC, directly acting oral anticoagulant; ICH, intracranial hemorrhage; MI, myocardial infarction; NICE, National
Institute for Health and Clinical Excellence; QALY, quality-adjusted life-year; RCT, randomized controlled trial; SE, systemic embolism; TIA,
transient ischemic attack.
aFor full justification, please see main text.
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respectively.24 No long-term management costs were
assumed to be incurred by patients experiencing an MI or
extracranial bleed. Following clinical advice, the post-ICH
management cost was assumed to be the same as the post-
stroke management cost, itself an average cost of manage-
ment of mild, moderate, and severely disabling stroke
reported by Luengo et al.25 The cost per cycle for patients
with a history of both stroke and ICH was assumed the
same as for a history of only one of these events.
Acute event disutilities and utilities per cycle are sum-
marized in Table 3. The disutilities for TIA and SE were
assumed to be the same and estimated using a UK stan-
dard gamble study of AF patients.26 The same study was
used to inform the disutility of a stroke or clinically rele-
vant (non-ICH) bleed. A computerized preference survey
of healthy US patients was used to estimate the disutility
of an ICH.27 A longitudinal study of English patients dis-
charged from hospital following acute MI provided an
EQ-5D-based estimate of MI disutility.28 The utility for a
cycle spent in the post stroke, MI, and ICH states was
based on a German cohort study of post stroke patients
using the German EQ-5D29; we used a beta distribution
for the post-ICH utility as this was based on only five
patients. The utility for post extracranial bleed was
assumed to be the same as for post stroke. Utilities for
chronic health states are assumed to be multiplicative.
For example, the utility of a patient who has experienced
both an ischemic stroke and a myocardial infarction will
be the product of the two utility scores. The state utilities
were assumed to reduce with age by factors estimated
relative to a reference age (65–75), based on general pop-
ulation EQ-5D utility estimates.30 Utilities were weighted
by the 60/40 gender split in gender so differences between
genders were not explicitly modelled.
Our model is fully probabilistic, and we will present
mean and 95% credible intervals (CrI) for the estimated
total and incremental costs, quality adjusted life-years
(QALYs), and net benefits. The upper and lower limits
of the 95% CrI correspond to the 2.5% and 97.5% per-
centiles of the probability sensitivity analysis samples. If
a 95% CrI for incremental costs, QALYs, or net benefits
excludes zero, it indicates at least 97.5% Bayesian prob-
ability that the comparator has a higher value than the
reference on that outcome.
Sensitivity Analyses
Sensitivity analyses were conducted to test the robustness
of the analysis to our assumptions. Two sensitivity analy-
ses were conducted analyzing cohorts initially aged 60 or
80 years old. Additionally, we explored the sensitivity toT
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warfarin monitoring costs, effects of ICH and bleed on
future mortality, treatment switching rules, the data for
our meta-analysis comparing warfarin and no treatment,
and the assumed hazard ratio of ICH on warfarin rela-
tive to no treatment. The base case assumes no long-term
management costs for MI so this was increased to £142
per year, in line with the Bayer single technology assess-
ment for rivaroxaban.10 The lower doses of 2.5 mg for
apixaban and 110 mg for dabigatran were explored as
treatment strategies in a further sensitivity. As the
DOACs are due to come off-patent and thus reduce in
price, threshold analyses were conducted to explore the
price at which each DOAC becomes the optimal strategy,
assuming other DOAC prices remain fixed. Monitoring
costs, priced at 50% those of warfarin, were added for
the DOACs. Changed all beta and uniform distributions
to Normal. Reran the model comparing DOACs and
warfarin for patients with a history of stroke. Reran
assuming patients do not switch treatment following MI
on dabigatran, as for other treatments. Table 9 in the
appendix provides more detail on these sensitivity
analyses.
Value of Information Analyses
To assess the impact of uncertainty on decision making
and measure the value of further research, expected value
of perfect information (EVPI) and expected value of par-
tial perfect information (EVPPI) were computed.31 The
EVPI and EVPPI measure the value of removing all
uncertainty around all or partial subsets of parameters,
respectively. If EVPPI for parameter subsets are close to
the total EVPI, it suggests the most important subsets
have been identified. Parameter subsets considered were
all costs, only event costs, only state costs, all utilities,
only event utilities, only state utilities, treatment switch-
ing probabilities, impact of past events on future risks,
baseline (warfarin) log hazards, and DOAC treatment
effects relative to warfarin. In addition, we calculated
EVPPI for the relative effects parameters that would be
informed by a two-arm RCT comparing the top two
cost-effective treatments, a three-arm RCT comparing
the top three cost-effective treatments, and so on for
four-arm and five-arm RCTs. Table 4 provides more
details on investigated parameter sets. EVPPI was esti-
mated using up to 128 inner samples and 1024 outer sam-
ples of Monte Carlo simulation, chosen to provide low
bias and variance in estimates.31,32 Assuming an inci-
dence of 1%,33 and that there are 500,000 70-year-olds in
England and Wales,34 there are 5000 new cases of AF
every year. Population EVPI and EVPPI were thereforeT
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calculated assuming 5000 new AF patients per year, dis-
counting at 3.5% per year, and summing over a 10-year
technology lifetime. As a sensitivity we also estimate
using a 2-year technology horizon to represent the impact
of patent expiry from 2020 onwards.
Results
The total and incremental costs, QALYs, and net benefits
at both a £20,000 and £30,000 willingness-to-pay threshold,
for a cohort with initial age 70, are presented in Table 3.
Cost-effectiveness acceptability curves are presented in
Figure 2. All the DOACs have higher expected incremental
net benefits than warfarin at both thresholds but only apix-
aban 5 mg had a 95% CrI that excluded zero. Apixaban 5
mg had the highest expected incremental net benefit and its
probability of having the greatest net benefit was close to
60% at both thresholds. Dabigatran 150 mg had the sec-
ond highest incremental net benefit and a probability of
having greatest net benefit above 20% for both thresholds.
The probability that warfarin had highest net benefit was
0% at both thresholds, indicating there is little uncertainty
that a DOAC is optimal. All DOACs except rivaroxaban
20 mg had lower expected costs than warfarin but all esti-
mates of incremental costs were uncertain with 95% CrI
crossing the zero line. All DOACs also had higher expected
QALYs but again all 95% CrI indicated high uncertainty.
Dabigatran 150 mg had the lowest expected costs while riv-
aroxaban 20 mg had the highest expected costs of all antic-
oagulants, including warfarin. Apixaban 5 mg had highest
expected QALYs while edoxaban 60 mg had lowest out of
the DOACs and warfarin had lowest overall.
Table 4 Expected Value of Partial Perfect Information Resultsa
Parameter Subset 2-Year Horizon, Mean (95% CrI) 10-Year Horizon, Mean (95% CrI)
All model parameters (total EVPI) £4.10 (4.00, 4.12) million £17.94 (17.85, 18.03) million
Relative effect of apixaban versus dabigatranb £1.82 (1.75, 1.88) million £7.95 (7.66, 8.24) million
Relative effects of apixaban versus dabigatran
versus rivaroxabanb
£2.49 (2.44, 2.55) million £10.92 (10.69, 11.16) million
Relative effects of apixaban versus dabigatran
versus rivaroxaban versus edoxabanb
£2.76 (2.70, 2.81) million £12.10 (11.86, 12.33) million
Relative effects of apixaban versus dabigatran
versus rivaroxaban versus edoxaban versus
warfarin
£2.82 (2.79, 2.84) million £12.33 (12.23, 12.43) million
Relative effects of apixaban versus dabigatran
versus warfarin
£1.93 (1.91, 1.96) million £8.47 (8.36, 8.57) million
Event costs, warfarin monitoring costs, and state
costs
£0 (0–17,586) £0 (0–76,995)
Event costs £0 (0–7569) £0 (0–33,139)
Warfarin monitoring costs £0 (0–76) £0 (0–335)
State costs £0 (0–7441) £0 (0–32,580)
Treatment switching probabilities £0 (0–193) £0 (0–843)
Impact of prior events (stroke, ICH, bleed, MI)
on risk of future events (stroke, TIA/SE, ICH,
bleed, death)
£ 0 (0–6547) £ 0 (0–28,663)
Baseline hazards for warfarin £8552 (0–15,128) £37,443 (0–66,236)
Treatment effect of warfarin relative to ‘‘no
treatment’’
£0 (0–20,230) £0 (0–88,573)
Event and state utilities and factors for reduction
in utility with age (informed by Kind et al.30)
£0 (0–13,398) £0 (0–58,661)
State utilities £0 (0–1563) £0 (0–6843)
Event utilities £0 (0–3,273) £0 (0–14,331)
CrI, credibility interval; EVPI, expected value of perfect information; EVPPI, expected value of partial perfect information; ICH, intracranial
hemorrhage; MI, myocardial infarction; SE, systemic embolism; TIA, transient ischemic attack.
aUsed 128 inner samples and 1024 outer samples to estimate the EVPI and EVPPI. We estimated 5000 new AF patients per year, discounted at
1.035, and summed over technology lifetime of 10 years to give a total of 43038.43 patients. Over technology lifetime of 2 years this gives
9830.918. This was multiplied by individual EVPI and EVPPI estimates to provide population estimates.
bEVPPI without warfarin required reparameterization of treatment effects in model. Fewer samples were required for similar precision and
accuracy. Results are based on 64 inner samples and 1024 outer samples.
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The estimated hazard ratios of events and their
expected impacts on costs and utilities explain these find-
ings. Table 8 in the appendix presents the proportion
lifetime spent with history of each of the events with life-
time consequences; these indicate stroke and ICH are
less common on DOACs than on Warfarin but extracra-
nial bleeds are more common. On the two most optimal
treatments, dabigatran has less common stroke and ICH
than apixaban but this is offset by more frequent MI
and extracranial bleeds.
Sensitivity analyses, results of which are summarized
in Table 9 of the appendix, confirmed that the conclu-
sion of apixaban 5 mg being optimal was robust to
assumptions in the model. Apixaban 5 mg was also opti-
mal in cohorts with initial age 60 or 80 years old. As
lower doses of apixaban and dabigatran are recom-
mended in older patients, 2.5 mg and 110 mg, respec-
tively, we conducted a sensitivity analysis with these
doses but apixaban remained optimal. However, war-
farin became optimal when it was assumed that patients
would always switch after a stroke, bleed, SE, TIA, ICH,
and MI (if on dabigatran), due to patients spending less
time on a DOAC. Sensitivity analysis demonstrated that,
holding prices of other treatments fixed, warfarin would
have to reduce from £404.52 to 2£1393.79, dabigatran
would have to reduce in annual price from £801.76 to
£487.86, edoxaban from £801.76 to £222.93, and rivarox-
aban from £766.52 to £201.47, to have greater net benefit
than apixaban. This represents a substantial discount
from their current prices; further details are provided in
Table 8 and Figure 4 of the appendix.
Results of the value of information analysis are sum-
marized in Table 4. Using a 10-year time horizon, the
total estimated population EVPI was £17.94 million
(17.85 million, 18.03 million), suggesting high potential
value in research reducing uncertainty about the cost-
effectiveness of DOAC treatment. The EVPPI was effec-
tively zero for all cost, utility, switching parameters, and
impact of previous events on future risk parameter sub-
sets, and was only £37,443 (0, 66,236) for event hazards
on warfarin. This minimal impact of cost uncertainty on
the results supports our threshold analysis that the con-
clusion of apixaban being optimal is relatively insensitive
to price reductions in other DOACs. The key uncertainty
contributing to EVPI is from the relative effectiveness of
the different anticoagulants. EVPPI for the relative effect
of apixaban versus dabigatran (the treatments with high-
est and second highest expected net benefit, respectively)
was £7.95 million (7.66 million, 8.24 million) but adding
the relative effect of rivaroxaban raises EVPPI to £10.92
million (10.69 million, 11.16 million) and further adding
edoxaban raises EVPPI to £12.10 million (11.86 million,
12.33 million). Further adding the relative effect of war-
farin (giving a five-arm RCT) only increases EVPPI to
£12.33 million (12.23 million, 2.43 million), suggesting
little additional value from including warfarin. Using
only 2-year time horizon, the population EVPI was £4.10
(4.08, 4.12) million and the EVPPI for an apixaban ver-
sus dabigatran trial was £1.82 (1.75, 1.88) million, still
suggesting potential value, although adding rivaroxaban
increases it to £2.49 (2.44, 2.55) million, which may be
more convincing. That the EVPPI are approaching the
total EVPI suggests the most important parameters,
namely, the relative effects, have been identified.
Discussion
At a willingness-to-pay threshold of £20,000 per QALY,
all DOACs had higher expected net benefit than war-
farin. Warfarin was dominated, with lower effects but
higher costs, than all DOACs except rivaroxaban and
had a 0% probability of having highest net benefit at
£20,000. There is considerable uncertainty between the
DOACs, but apixaban 5 mg twice daily had the highest
expected net benefit and the highest probability (60%) of
having highest net benefit as first-line anticoagulant for
the prevention of stroke in AF. This conclusion held for
Figure 2 Cost-effectiveness acceptability curves. The
probability each first-line treatment is has highest net benefit
against willingness to pay per QALY threshold. Adapted from
Sterne (2017)15 under Creative Commons Attribution (CC BY
4.0) license.
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cohorts of initial age 60, 70, and 80. Conclusions were
robust to all sensitivity analyses except when assuming
patients switch to warfarin following any adverse clinical
event, when warfarin is optimal. The differences in life-
time total cost, QALYs, and net benefit, compared with
the totals, were very small and the 95% credible intervals
were overlapping. Our results therefore highlight uncer-
tainty as to which DOAC is optimal.
Value of information analysis suggested there was
potential value in reducing uncertainty in relative effi-
cacy of the DOACs, but limited value in further warfarin
comparisons or investigating other model inputs such as
costs. In addition to directing future research, EVPI and
EVPPI quantify the sensitivity of the decision to para-
meter uncertainty by combining the probability that a
decision is wrong with the consequences of a wrong deci-
sion.35 However, EVPPI assumes all uncertainty is elimi-
nated, while in practice the uncertainty reduction will
depend on sample size and follow-up time. Given the
low event rates and chronic nature of AF, a very large
trial may be required and the costs of such a trial may
well not outweigh the benefits. Of the research designs
we explored, a two-arm RCT comparing apixaban ver-
sus dabigatran is most likely to be value for money. An
expected value of sample information (EVSI) and
expected net benefit of sampling (ENBS) analysis is
required.36 However, the nonlinearity of the net benefit
function and high dimensionality and correlation of the
input parameters for our model makes nested Monte
Carlo simulation infeasible. Efficient approximation
methods for EVSI exist but rely on the suitability of a
linear approximation, which is not appropriate for our
model.37,38 This is an area for further research.39
That apixaban 5 mg had the greatest expected net ben-
efit was driven by its higher expected QALYs than dabi-
gatran. As stroke and MI have similar chronic health
utilities and acute disutilities (Table 2), these higher
QALYs were explained by the advantage of apixaban
over dabigatran on hazard of MI being greater than its
disadvantage on stroke reduction. That dabigatran 150
mg had the lowest expected costs is driven by its low
hazard of ICH and stroke, the events with highest acute
costs (Table 2), which overcame its greater hazard of MI,
which had a lower acute cost. However, apixaban 5 mg
also had low expected costs due to its low hazard of ICH,
so the finding that it has the highest expected net benefits
is still driven by the advantage on QALYs. Conversely,
rivaroxaban 20 mg had the highest expected cost primar-
ily because of its limited reduction in ICH risk, which
drove its low incremental net benefit over warfarin. All
DOACs had similar reduction in risk of death compared
to warfarin and so this was not a key driver of the model
results.
On the efficacy and safety parameters, there were no
direct head-to-head RCT comparisons between different
DOAC drugs—all such comparisons were based on indi-
rect evidence derived from the networks. Also, the pro-
file of patients entering trials may not be the same as
those treated in practice, who may be older and have
more comorbidities. Considering AF is a lifetime chronic
condition, the trials have also been of relatively short
duration. We relied on warfarin arms of the trials to esti-
mate absolute event rates but reliable estimation of cost-
effectiveness in different clinical scenarios requires high-
quality data on absolute event rates. NHS health record
data could provide further evidence on absolute event
rates. Rare adverse effects that remained undetected dur-
ing drug development may come to light with high-
volume use post licensing.
Our model made various simplifying assumptions. We
assumed that nonmortality event rates do not depend on
age. We do not distinguish between minor and major
stroke and assume the split of minor and major stroke
does not differ across treatments. Some previous models
split stroke by severity40–42 but we found insufficient evi-
dence to estimate rates differentially. Following an MI,
we assumed patients on dabigatran switch to warfarin,
but those on other DOACs do not switch. We only con-
sidered simple treatment sequences of first-line DOAC
followed by warfarin followed by no treatment or first-
line warfarin followed by no treatment; wider compari-
son of sequences of DOACs and warfarin could be inter-
esting for future research. We assumed that SE and TIA
are transient events with no long-term consequences.
However, severe consequences such as limb loss are
extremely rare, so are unlikely to affect results. We did
not account for costs due to unrelated diseases, which
can reduce the cost-effectiveness of interventions that
extend life; however, there is not yet consensus on how
to account for unrelated costs and including them is not
standard practice.43 Finally, we do not distinguish
between types of AF despite increasing evidence that
stroke risk increases as AF progresses from paroxysmal
to persistent to permanent.44,45
In addition to using RCTs to estimate relative effects,
we also used their warfarin arms to estimate baseline
event risks. Baseline characteristics across RCTs were
similar, suggesting our first-line population of interest
could be similar across populations. In practice, how-
ever, patients may be older and have more comorbidities.
Time in therapeutic range for warfarin varied consider-
ably in the RCTs and may be lower in practice.15
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Although registry studies in Danish and Swedish popula-
tions have been published, we could not identify studies
in the United Kingdom.21,22 These limitations prevent us
from making rigorous patient-specific recommendations;
the similarity in net benefits across DOACs suggest the
choice be left to physicians for individual patients. If the
necessary RCT data could be obtained, NMA using indi-
vidual participant data to identify optimal patient popu-
lations could be useful further research.46
The use of DOACs may be associated with a number
of issues including class- and drug-specific cautions and
contraindications, the potential for subtherapeutic dos-
ing, reduced adherence due to lack of regular monitor-
ing, absence of, or limited experience with antidotes, as
well as the added cost of maintaining stocks of numerous
different anticoagulants and the potential for prescribing
errors due to unfamiliarity. We have not accounted for
these in this model because the impact of some of these
potential problems is untested within RCTs and will only
emerge once uptake of the drugs is greater. Despite
NICE estimates that 29% and 22.5% of AF patients
received no treatment or only aspirin, respectively, we
did not model these as they are no longer recommended.7
Previous studies have demonstrated cost-effectiveness of
warfarin over aspirin.47,48 We can therefore infer that
DOACs would be cost-effective compared with aspirin
and no treatment. Patients currently on aspirin or no
treatment due to difficulties on warfarin may now be
offered DOACs.
Several cost-effectiveness analyses of DOACs com-
pared to warfarin for the prevention of stroke in AF in
the UK context have been published.10–14 These found
individual DOACs to be cost-effective compared to war-
farin, in line with our finding that all DOACs have
greater expected net benefits than warfarin. The NICE
technology appraisals (TA) also found DOACs to be
cost-effective and recommended dabigatran (TA249),
rivaroxaban (TA256), apixaban (TA275), and edoxaban
(TA355). Three published cost-effectiveness analyses
compared apixaban, rivaroxaban, dabigatran, and war-
farin.12–14 Of these, only Verhoef et al.13 disagreed with
our finding that apixaban was the optimal; these authors
found dabigatran 150 mg to be the optimal. This differ-
ence is likely because their model had only a single post-
event disability state, so did not include the impact of MI
on future event risks. Dabigatran’s higher risk of MI is
lessened if the consequent increase in stroke, death, and
TIA/SE risk is omitted. In addition, all previous analyses
used only single pivotal trials on each DOAC and did not
use NMA. They also did not include edoxaban. Multiple
treatment assessments of the DOACs conducted in other
countries support our finding that apixaban was optimal,
including in the United States,49,50 Belgium,51,52 France,53
and Taiwan.54
Our study is the first to simultaneously compare the
cost-effectiveness in the UK context of all licensed antic-
oagulants, including edoxaban 60 mg, and to make use
of all available evidence through NMA. Ours is also the
first to include comprehensive value of information anal-
ysis. Our findings, in particular that apixaban 5 mg twice
daily is optimal, will be useful for guidelines and practice,
while our value of information analysis may direct future
research.
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